If BPC-157 Isn't Approved, Why Can Anyone Buy It Online?

BPC-157 is not approved as a medicine in any country, yet it is sold openly online and turns up in influencer videos alongside TB-500 and Melanotan II. Both things are true because US drug law is mostly enforced after the fact. FDA does not check websites before they open, its main tool against them is a warning letter that its own manual calls "informal and advisory", and much of the supply is reported to come from overseas.¹²³

Being on sale is not the same as being allowed. Sellers label the vials "research use only", but FDA judges a product by its intended use and has told sellers that the label does not stop products meant for people being unapproved drugs.⁴⁵ And the "moved to Category 2" news that many people have heard dates from 2023. BPC-157 has since left that list, yet as of 22 October 2026 US pharmacies still have no federal route to compound it.⁶⁷

This article explains how those pieces fit together. It describes regulation only, gives no dosing information, recommends no products and is not legal or medical advice.

"Research use only" is a label, not a permission

Federal rules let some drugs be shipped without directions for use to people engaged "in research not involving clinical use, or in chemical analysis", if the drug is used only for that purpose.⁸ That exemption is what the label is reaching for. But FDA decides what a product is by its "intended uses", which "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article."⁴

FDA's letters apply that test plainly. In August 2026 it told an online seller: "Despite statements on your product labeling marketing your products for 'research use only' and 'not for human consumption,' evidence obtained from your website establishes that your products are intended to be drugs for human use."⁵ The claims FDA quoted were written in research language, such as a product being "Investigated for influence on appetite regulation and satiety pathways." FDA also said that selling water for preparing injections alongside the vials provided "the means to prepare an injectable drug for human administration."⁵ It used the same reasoning in December 2024, against a seller whose labels said "FOR RESEARCH USE ONLY".⁹

So the label does not make human sales legal. It mainly gives sellers a story to tell. Our explainer on what the "research use only" label means looks at the wording in more detail.

Why the websites keep trading

Nobody approves a website in advance. FDA finds problems later, then writes to the seller. Its Regulatory Procedures Manual says a warning letter "is informal and advisory. It communicates the agency's position on a matter, but it does not commit FDA to taking enforcement action."² The letters ask for a reply within fifteen working days and warn that failure to fix the problems "may result in legal action including, without limitation, seizure and injunction."⁹

Much of the supply is overseas. The Associated Press reported in October 2026 that grey-market peptides "made in China and other countries" remain "widely available for purchase via online platforms like TikTok."³ INTERPOL said in May 2026 that peptides are "widely sold as 'research chemicals' or 'cosmetic peptides' to avoid detection".¹⁰

Enforcement is uneven. The 2024 to 2026 FDA letters to "research" websites that we read centred on weight-loss peptides such as semaglutide and retatrutide.⁵⁹¹¹ BPC-157 and TB-500 did appear in a 2023 letter to one seller.¹² We found no published count of how many sites sell BPC-157 or how many have been warned.

That does not mean nothing happens. The seller warned in that 2023 letter, whose "research purpose only" products included BPC-157 and TB-500, kept selling, including to an undercover law enforcement account, according to federal prosecutors; he was sentenced in February 2025 to one year of supervised release and $100,000 in forfeiture.¹²¹³ Internationally, INTERPOL's Operation Pangea XVIII, run across 90 countries including the United States from 10 to 23 March 2026, "disrupted approximately 5,700 criminal-linked websites, social media pages, channels and automated bots used to market and sell illicit medicines".¹⁰ No regulator we checked publishes how often a closed site reopens under a new name.

What "moved to Category 2" meant, and where BPC-157 stands now

Category 1 and Category 2 are FDA's sorting lists for ingredients nominated for use by compounding pharmacies. Category 2 is its group of substances that may present significant safety risks in compounding.⁶ In our reading, these lists govern what licensed pharmacies may make; they never applied to "research" websites, which were already selling unapproved drugs. That is why the Category 2 decision did not empty the online market, and why leaving Category 2 did not make online sales legal.

The dates, because some sites still present the 2023 change as current:

• 29 September 2023: FDA added BPC-157 to Category 2.⁶
• 15 to 22 April 2026: FDA gave seven days' notice and then removed BPC-157 from Category 2 "because the nominations were withdrawn by the nominators". It did not move it to Category 1.⁷
• 23 July 2026: FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the bulks list. ABC News reported that the vote "is non-binding and still needs sign-off from the FDA."¹⁴
• 14 October 2026: FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs. On 22 October 2026 it was still listed as pending review, and we found no Federal Register notice.¹⁵ The AP reported, citing two unnamed people, that it is meant to let pharmacies "temporarily compound some of the most popular peptides, including BPC-157".³ Its text is unpublished, so which peptides and conditions it covers is unknown.

Right now, a 503A pharmacy may use a bulk ingredient only if it meets a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list.¹⁶ BPC-157 has none of these, is not in the "Category 1" group FDA tolerates while it decides, and is absent from the 503B list used by outsourcing facilities.⁷¹⁷ FDA said as much to one pharmacy in 2019: drug products made with BPC-157 acetate "are not eligible for the exemptions provided by section 503A(a)".¹⁸ Even if the interim policy allows compounding, compounded drugs are not FDA-approved, and FDA "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."¹⁹

FDA's safety page still says "the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."⁶ Our dated BPC-157 timeline has the full record, our explainer on the interim access plan covers what it might change, and our guide to compounded peptides explains the pharmacy rules.

Clinics, telehealth and influencers

When FDA searched online for its July 2026 review, it found "websites of compounding pharmacies as well as several med spas and clinics in the United States" mentioning BPC-157 for uses from gut health to joint support.¹ A prescription does not change a substance's status: doctors can prescribe approved medicines for unapproved uses, but BPC-157 has no approved product to prescribe.¹ In March 2026 FDA warned 30 telehealth companies over marketing that implied "sameness with FDA-approved products".²⁰ Our guide to peptides through telehealth lists questions to ask if that route opens up.

There is no public data on where individual influencers get their supply. What is documented is how the promotion pays. Writing in The Conversation in May 2026, researchers from Swansea University and the University of Queensland described influencers giving followers personalised discount codes worth "between 5% and 30% off", with each sale "generating commission for the influencer".²¹ Under the FTC's Endorsement Guides, a material connection the audience would not expect must be disclosed "clearly and conspicuously", material connections include "the provision of free or discounted products", and endorsers themselves "may be liable" for claims they know or should know are deceptive.²² FDA said in September 2025 that "undisclosed paid influencer promotion" has "blurred the lines among editorial content, user-generated media and pharmaceutical advertising".²³

Popularity is not evidence. Our guide to checking peptide claims on social media helps, and for BPC-157 see what the human tendon studies actually show.

Is it illegal to buy?

The provisions FDA cites in these letters are aimed at introducing unapproved drugs into interstate commerce, which means the people who make, ship and sell them.⁵ We found no federal provision that makes simply buying or owning BPC-157 a crime. Importing is treated more strictly: FDA says that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use". Its staff may use discretion only in narrow cases, such as a serious condition with no effective treatment available in the US, and can refuse shipments that look commercial or risky.²⁴ State laws may add rules. This is a general description, not legal advice.

Other regulators take the same line on the label. The TGA in Australia says a "research use only" disclaimer "does not make its supply lawful" and that promoting unapproved peptides "particularly through social media or influencer channels, is likely to breach Australian therapeutic goods advertising laws."²⁵ Health Canada says "For Research Use Only" labelling "does not make these products legal".²⁶ In the UK, the MHRA's criminal enforcement unit made two arrests in May 2026 at a site it believes made and distributed unlicensed weight-loss medicines "as well as peptide products".²⁷ Our guide are peptides legal? compares the UK, EU, Australia and Canada.

What being on sale does not tell you

An approved medicine has been through checks that a research vial has not. FDA reviews whether its maker can manufacture to federal quality standards and judges, from laboratory, animal and human testing, that benefits outweigh risks for the intended use.²⁸ Every batch sold as sterile or pyrogen-free must be laboratory tested.²⁹ Unapproved versions "do not undergo FDA's review for safety, effectiveness and quality",¹¹ and when FDA examined BPC-157 certificates of analysis for its July 2026 review, it found most "only contain purity testing results".¹ For the one use it reviewed, it found "a lack of evidence" that BPC-157 works.¹

Sterility and endotoxin testing matter most for anything injected. Our companion article on whether online peptides are safe to inject covers what laboratory tests have found, and approved versus unapproved peptides explains the difference in more depth.

If you want access to an unapproved peptide, the legal routes are narrow. A clinical trial is the main one; expanded access outside a trial is limited to serious or life-threatening conditions with no satisfactory alternative.³⁰ See how clinical trials work and our guide on joining a trial instead of buying online. FDA's warning signs for online sellers include not requiring a screening and prescription by a licensed doctor, incorrect pharmacy addresses on the label and prices that seem too good to be true.¹¹

If you have injected a product and feel unwell, contact a doctor and bring the vial. Seek urgent care for trouble breathing, swelling of the face or throat, chest pain, or fever with a hot, red, spreading area around the injection site. Report problems to FDA's MedWatch programme, or to your national regulator outside the US.